{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,9]],"date-time":"2026-09-09T18:59:32Z","timestamp":1788980372844,"version":"build-2803163510"},"reference-count":57,"publisher":"Elsevier BV","issue":"9","license":[{"start":{"date-parts":[[2022,9,1]],"date-time":"2022-09-01T00:00:00Z","timestamp":1661990400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,9,1]],"date-time":"2022-09-01T00:00:00Z","timestamp":1661990400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,9,2]],"date-time":"2023-09-02T00:00:00Z","timestamp":1693612800000},"content-version":"vor","delay-in-days":366,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","valueinhealthjournal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Value in Health"],"published-print":{"date-parts":[[2022,9]]},"DOI":"10.1016\/j.jval.2022.02.008","type":"journal-article","created":{"date-parts":[[2022,3,23]],"date-time":"2022-03-23T21:28:59Z","timestamp":1648070939000},"page":"1644-1653","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":32,"title":["Systematic Review of Cost-Utility Analyses That Have Included Carer and Family Member Health-Related Quality of Life"],"prefix":"10.1016","volume":"25","author":[{"given":"Alison","family":"Scope","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arjun","family":"Bhadhuri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Becky","family":"Pennington","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jval.2022.02.008_bib1","doi-asserted-by":"crossref","first-page":"i1651","DOI":"10.1136\/bmj.i1651","article-title":"The need to \u201ccarer proof\u201d healthcare decisions: such decisions may have important effects on family carers; decision making should formally consider them","volume":"352","author":"Al-Janabi","year":"2016","journal-title":"BMJ"},{"issue":"4","key":"10.1016\/j.jval.2022.02.008_bib2","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1016\/j.jhealeco.2010.05.003","article-title":"Caring for and caring about: disentangling the caregiver effect and the family effect","volume":"29","author":"Bobinac","year":"2010","journal-title":"J\u00a0Health Econ"},{"issue":"6","key":"10.1016\/j.jval.2022.02.008_bib3","doi-asserted-by":"crossref","first-page":"975","DOI":"10.1016\/j.jval.2012.05.009","article-title":"The inclusion of informal care in applied economic evaluation: a review","volume":"15","author":"Goodrich","year":"2012","journal-title":"Value Health"},{"issue":"4","key":"10.1016\/j.jval.2022.02.008_bib4","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1007\/s40273-019-00788-3","article-title":"Family and caregiver spillover effects in cost-utility analyses of Alzheimer\u2019s disease interventions","volume":"37","author":"Lin","year":"2019","journal-title":"Pharmacoeconomics"},{"issue":"2","key":"10.1016\/j.jval.2022.02.008_bib5","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1007\/s40258-018-0436-0","article-title":"Family spillover effects in pediatric cost-utility analyses","volume":"17","author":"Lavelle","year":"2019","journal-title":"Appl Health Econ Health Policy"},{"issue":"10","key":"10.1016\/j.jval.2022.02.008_bib6","doi-asserted-by":"crossref","first-page":"1349","DOI":"10.1016\/j.jval.2020.05.017","article-title":"Inclusion of carer health-related quality of life in National Institute for Health and Care Excellence appraisals","volume":"23","author":"Pennington","year":"2020","journal-title":"Value Health"},{"issue":"4","key":"10.1016\/j.jval.2022.02.008_bib7","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1007\/s40273-018-0730-6","article-title":"The inclusion of spillover effects in economic evaluations: not an optional extra","volume":"37","author":"Brouwer","year":"2019","journal-title":"Pharmacoeconomics"},{"issue":"10","key":"10.1016\/j.jval.2022.02.008_bib9","doi-asserted-by":"crossref","first-page":"1093","DOI":"10.1001\/jama.2016.12195","article-title":"Recommendations for conduct, methodological practices, and reporting of cost-effectiveness analyses: Second Panel on Cost-Effectiveness in Health and Medicine","volume":"316","author":"Sanders","year":"2016","journal-title":"JAMA"},{"issue":"2","key":"10.1016\/j.jval.2022.02.008_bib12","first-page":"63","article-title":"Cost-effectiveness of florbetapir-PET in Alzheimer\u2019s disease: a Spanish societal perspective","volume":"18","author":"Hornberger","year":"2015","journal-title":"J\u00a0Ment Health Policy Econ"},{"issue":"3","key":"10.1016\/j.jval.2022.02.008_bib13","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1017\/S026646231900028X","article-title":"Incorporating household spillovers in cost utility analysis: a case study using behavior change in COPD","volume":"35","author":"Bhadhuri","year":"2019","journal-title":"Int J Technol Assess Health Care"},{"issue":"1","key":"10.1016\/j.jval.2022.02.008_bib14","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1177\/0272989X08324955","article-title":"Cost-effectiveness of rotavirus vaccination: exploring caregiver(s) and \u201cno medical care\u201d disease impact in Belgium","volume":"29","author":"Bilcke","year":"2009","journal-title":"Med Decis Mak"},{"issue":"7","key":"10.1016\/j.jval.2022.02.008_bib15","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1177\/0004867418823272","article-title":"Economic evaluation of stepped care for the management of childhood anxiety disorders: results from a randomised trial","volume":"53","author":"Chatterton","year":"2019","journal-title":"Aust N Z J Psychiatry"},{"key":"10.1016\/j.jval.2022.02.008_bib16","doi-asserted-by":"crossref","first-page":"g5725","DOI":"10.1136\/bmj.g5725","article-title":"Re-evaluating cost effectiveness of universal meningitis vaccination (Bexsero) in England: modelling study","volume":"349","author":"Christensen","year":"2014","journal-title":"BMJ"},{"issue":"10","key":"10.1016\/j.jval.2022.02.008_bib17","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3310\/hta23100","article-title":"Goal-oriented cognitive rehabilitation for early-stage Alzheimer\u2019s and related dementias: the GREAT RCT","volume":"23","author":"Clare","year":"2019","journal-title":"Health Technol Assess"},{"issue":"38","key":"10.1016\/j.jval.2022.02.008_bib18","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3310\/hta19380","article-title":"Treatment of childhood anxiety disorder in the context of maternal anxiety disorder: a randomised controlled trial and economic analysis","volume":"19","author":"Creswell","year":"2015","journal-title":"Health Technol Assess"},{"issue":"52","key":"10.1016\/j.jval.2022.02.008_bib19","doi-asserted-by":"crossref","first-page":"7601","DOI":"10.1016\/j.vaccine.2012.10.034","article-title":"Effectiveness and cost-effectiveness of pediatric rotavirus vaccination in British Columbia: a model-based evaluation","volume":"30","author":"Fisman","year":"2012","journal-title":"Vaccine"},{"issue":"1","key":"10.1016\/j.jval.2022.02.008_bib20","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1093\/ageing\/afh232","article-title":"Occupational therapy compared with social work assessment for older people. An economic evaluation alongside the CAMELOT randomised controlled trial","volume":"34","author":"Flood","year":"2005","journal-title":"Age Ageing"},{"issue":"8","key":"10.1016\/j.jval.2022.02.008_bib21","doi-asserted-by":"crossref","first-page":"2212","DOI":"10.1161\/STROKEAHA.115.008585","article-title":"Cluster randomized controlled trial: clinical and cost-effectiveness of a system of longer-term stroke care","volume":"46","author":"Forster","year":"2015","journal-title":"Stroke"},{"issue":"7","key":"10.1016\/j.jval.2022.02.008_bib22","doi-asserted-by":"crossref","first-page":"617","DOI":"10.2165\/00019053-200826070-00008","article-title":"Cost-effectiveness analyses of natalizumab (Tysabri) compared with other disease-modifying therapies for people with highly active relapsing-remitting multiple\u00a0sclerosis in the UK","volume":"26","author":"Gani","year":"2008","journal-title":"Pharmacoeconomics"},{"issue":"5","key":"10.1016\/j.jval.2022.02.008_bib23","doi-asserted-by":"crossref","first-page":"411","DOI":"10.2165\/11531870-000000000-00000","article-title":"Cost effectiveness of donepezil in the treatment of mild to moderate Alzheimer\u2019s disease: a UK evaluation using discrete-event simulation","volume":"28","author":"Getsios","year":"2010","journal-title":"Pharmacoeconomics"},{"issue":"1","key":"10.1016\/j.jval.2022.02.008_bib24","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1016\/j.jalz.2010.07.001","article-title":"An economic evaluation of early assessment for Alzheimer\u2019s disease in the United Kingdom","volume":"8","author":"Getsios","year":"2012","journal-title":"Alzheimers Dement"},{"issue":"3","key":"10.1016\/j.jval.2022.02.008_bib25","doi-asserted-by":"crossref","first-page":"e591","DOI":"10.1542\/peds.2010-0796","article-title":"Use of models to identify cost-effective interventions: pertussis vaccination for pediatric health care workers","volume":"128","author":"Greer","year":"2011","journal-title":"Pediatrics"},{"issue":"1","key":"10.1016\/j.jval.2022.02.008_bib26","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1186\/1471-2377-12-2","article-title":"Evaluating the cost effectiveness of donepezil in the treatment of Alzheimer\u2019s disease in Germany using discrete event simulation","volume":"12","author":"Hartz","year":"2012","journal-title":"BMC Neurol"},{"issue":"5","key":"10.1016\/j.jval.2022.02.008_bib27","doi-asserted-by":"crossref","first-page":"e408","DOI":"10.1200\/JOP.2016.018036","article-title":"Economic evaluation of a hospital-based palliative care program","volume":"13","author":"Isenberg","year":"2017","journal-title":"J\u00a0Oncol Pract"},{"issue":"6","key":"10.1016\/j.jval.2022.02.008_bib28","first-page":"748","article-title":"Cost-effectiveness of a pentavalent human-bovine reassortant rotavirus vaccine for children \u22645 years of age in Taiwan","volume":"14","author":"Itzler","year":"2011","journal-title":"J\u00a0Med Econ"},{"issue":"44","key":"10.1016\/j.jval.2022.02.008_bib29","doi-asserted-by":"crossref","first-page":"6121","DOI":"10.1016\/j.vaccine.2009.08.030","article-title":"The cost-effectiveness of rotavirus vaccination: comparative analyses for five European countries and transferability in Europe","volume":"27","author":"Jit","year":"2009","journal-title":"Vaccine"},{"issue":"20","key":"10.1016\/j.jval.2022.02.008_bib30","doi-asserted-by":"crossref","first-page":"3971","DOI":"10.1016\/j.vaccine.2007.02.070","article-title":"Evaluating rotavirus vaccination in England and Wales. Part II. The potential cost-effectiveness of vaccination","volume":"25","author":"Jit","year":"2007","journal-title":"Vaccine"},{"issue":"3","key":"10.1016\/j.jval.2022.02.008_bib31","first-page":"215","article-title":"Cost-utility analysis of levodopa carbidopa intestinal gel (Duodopa) in the treatment of advanced Parkinson\u2019s disease in patients in Scotland and Wales","volume":"22","author":"Kalabina","year":"2019","journal-title":"J\u00a0Med Econ"},{"issue":"28","key":"10.1016\/j.jval.2022.02.008_bib32","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3310\/hta22280","article-title":"Aerobic and strength training exercise programme for cognitive impairment in people with mild to moderate dementia: the DAPA RCT","volume":"22","author":"Lamb","year":"2018","journal-title":"Health Technol Assess"},{"issue":"3 Pt 2","key":"10.1016\/j.jval.2022.02.008_bib33","doi-asserted-by":"crossref","first-page":"1274","DOI":"10.1016\/j.ajog.2005.05.042","article-title":"Acyclovir prophylaxis for pregnant women with a known history of herpes simplex virus: a cost-effectiveness analysis","volume":"193","author":"Little","year":"2005","journal-title":"Am J Obstet Gynecol"},{"issue":"11","key":"10.1016\/j.jval.2022.02.008_bib34","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0079797","article-title":"Cost-effectiveness of one year dementia follow-up care by memory clinics or general practitioners: economic evaluation of a randomised controlled trial","volume":"8","author":"Meeuwsen","year":"2013","journal-title":"PLoS One"},{"issue":"5","key":"10.1016\/j.jval.2022.02.008_bib35","doi-asserted-by":"crossref","first-page":"706","DOI":"10.1016\/j.vaccine.2007.11.064","article-title":"Cost and cost-effectiveness of childhood vaccination against rotavirus in France","volume":"26","author":"Melliez","year":"2008","journal-title":"Vaccine"},{"issue":"6","key":"10.1016\/j.jval.2022.02.008_bib36","doi-asserted-by":"crossref","first-page":"888","DOI":"10.1111\/j.1524-4733.2009.00534.x","article-title":"Budget impact and cost-effectiveness of including a pentavalent rotavirus vaccine in the New Zealand childhood immunization schedule","volume":"12","author":"Milne","year":"2009","journal-title":"Value Health"},{"issue":"6","key":"10.1016\/j.jval.2022.02.008_bib37","doi-asserted-by":"crossref","first-page":"1138","DOI":"10.1212\/WNL.52.6.1138","article-title":"Cost-effectiveness of donepezil in the treatment of mild or moderate Alzheimer\u2019s disease","volume":"52","author":"Neumann","year":"1999","journal-title":"Neurology"},{"issue":"52","key":"10.1016\/j.jval.2022.02.008_bib38","doi-asserted-by":"crossref","first-page":"8851","DOI":"10.1016\/j.vaccine.2007.10.009","article-title":"The cost-effectiveness of rotavirus vaccination in Australia","volume":"25","author":"Newall","year":"2007","journal-title":"Vaccine"},{"issue":"64","key":"10.1016\/j.jval.2022.02.008_bib39","first-page":"1","article-title":"Individual cognitive stimulation therapy for dementia: a clinical effectiveness and cost-effectiveness pragmatic, multicentre, randomised controlled trial","volume":"19","author":"Orgeta","year":"2015"},{"issue":"2","key":"10.1016\/j.jval.2022.02.008_bib40","doi-asserted-by":"crossref","first-page":"121","DOI":"10.3109\/14767058.2014.909803","article-title":"Resuscitation of neonates at 23 weeks\u2019 gestational age: a cost-effectiveness analysis","volume":"28","author":"Partridge","year":"2015","journal-title":"J\u00a0Matern Fetal Neonatal Med"},{"issue":"3","key":"10.1016\/j.jval.2022.02.008_bib41","first-page":"166","article-title":"Socio-economic modeling of rotavirus vaccination in Castilla y Le\u00f3n, Spain","volume":"19","author":"P\u00e9rez-Rubio","year":"2011","journal-title":"Infez Med"},{"issue":"18","key":"10.1016\/j.jval.2022.02.008_bib42","first-page":"1","article-title":"End-of-life care interventions: an economic analysis","volume":"14","author":"Pham","year":"2014","journal-title":"Ont Health Technol Assess Ser"},{"issue":"50","key":"10.1016\/j.jval.2022.02.008_bib43","doi-asserted-by":"crossref","first-page":"7105","DOI":"10.1016\/j.vaccine.2009.09.057","article-title":"Cost-effectiveness of a 3-dose pneumococcal conjugate vaccine program in the province of Quebec, Canada","volume":"27","author":"Poirier","year":"2009","journal-title":"Vaccine"},{"issue":"1","key":"10.1016\/j.jval.2022.02.008_bib44","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1111\/j.1360-0443.2012.04002.x","article-title":"Treating alcoholism reduces financial burden on care-givers and increases quality-adjusted life years","volume":"108","author":"Salize","year":"2013","journal-title":"Addiction"},{"issue":"5","key":"10.1016\/j.jval.2022.02.008_bib45","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1007\/s40273-015-0259-x","article-title":"Probabilistic Markov model estimating cost effectiveness of methylphenidate osmotic-release oral system versus immediate-release methylphenidate in children and adolescents: which information is needed?","volume":"33","author":"Schawo","year":"2015","journal-title":"Pharmacoeconomics"},{"issue":"30","key":"10.1016\/j.jval.2022.02.008_bib46","doi-asserted-by":"crossref","first-page":"4025","DOI":"10.1016\/j.vaccine.2009.04.030","article-title":"Impact of transmission dynamics on the cost-effectiveness of rotavirus vaccination","volume":"27","author":"Shim","year":"2009","journal-title":"Vaccine"},{"issue":"8","key":"10.1016\/j.jval.2022.02.008_bib47","doi-asserted-by":"crossref","first-page":"1059","DOI":"10.1002\/mds.26217","article-title":"Economic evaluation of occupational therapy in Parkinson\u2019s disease: a randomized controlled trial","volume":"30","author":"Sturkenboom","year":"2015","journal-title":"Mov Disord"},{"issue":"1","key":"10.1016\/j.jval.2022.02.008_bib48","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1186\/s12887-016-0632-8","article-title":"Cost-effectiveness and cost-utility analyses of hospital-based home care compared to hospital-based care for children diagnosed with type 1 diabetes; a randomised controlled trial; results after two years' follow-up","volume":"16","author":"Tiberg","year":"2016","journal-title":"BMC Pediatr"},{"issue":"43","key":"10.1016\/j.jval.2022.02.008_bib49","doi-asserted-by":"crossref","first-page":"7463","DOI":"10.1016\/j.vaccine.2011.07.056","article-title":"Cost-effectiveness of universal rotavirus vaccination in reducing rotavirus gastroenteritis in Ireland","volume":"29","author":"Tilson","year":"2011","journal-title":"Vaccine"},{"issue":"8","key":"10.1016\/j.jval.2022.02.008_bib50","doi-asserted-by":"crossref","first-page":"1521","DOI":"10.1016\/j.vaccine.2011.11.052","article-title":"Health economics of rotavirus immunization in Vietnam: potentials for favorable cost-effectiveness in developing countries","volume":"30","author":"Tu","year":"2012","journal-title":"Vaccine"},{"key":"10.1016\/j.jval.2022.02.008_bib51","first-page":"04","article-title":"Cost effectiveness of Nusinersen in the treatment of patients with infantile-onset and later-onset spinal muscular atrophy in Sweden","volume":"04","author":"Zuluaga-Sanchez","year":"2019","journal-title":"Pharmacoeconomics"},{"issue":"4","key":"10.1016\/j.jval.2022.02.008_bib52","doi-asserted-by":"crossref","first-page":"751","DOI":"10.1016\/j.jhealeco.2004.12.002","article-title":"Implications of spillover effects within the family for medical cost-effectiveness analysis","volume":"24","author":"Basu","year":"2005","journal-title":"J\u00a0Health Econ"},{"issue":"1","key":"10.1016\/j.jval.2022.02.008_bib53","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1097\/INF.0b013e3181b41506","article-title":"Health-related quality of life lost to rotavirus-associated gastroenteritis in children and their parents: a Canadian prospective study","volume":"29","author":"Brisson","year":"2010","journal-title":"Pediatr Infect Dis J"},{"issue":"2","key":"10.1016\/j.jval.2022.02.008_bib54","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1007\/s40273-014-0218-y","article-title":"Does including informal care in economic evaluations matter? A systematic review of inclusion and impact of informal care in cost-effectiveness studies","volume":"33","author":"Krol","year":"2015","journal-title":"Pharmacoeconomics"},{"issue":"4","key":"10.1016\/j.jval.2022.02.008_bib56","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1007\/s40273-019-00768-7","article-title":"Spillover effects on caregivers\u2019 and family members\u2019 utility: a systematic review of the literature","volume":"37","author":"Wittenberg","year":"2019","journal-title":"Pharmacoeconomics"},{"issue":"3","key":"10.1016\/j.jval.2022.02.008_bib57","doi-asserted-by":"crossref","first-page":"458","DOI":"10.1177\/0272989X10381280","article-title":"Estimation of a preference-based carer experience scale","volume":"31","author":"Al-Janabi","year":"2010","journal-title":"Med Decis Making"},{"key":"10.1016\/j.jval.2022.02.008_bib58","doi-asserted-by":"crossref","DOI":"10.1016\/j.socscimed.2021.114556","article-title":"The relative value of carer and patient quality of life: a person trade-off (PTO) study","volume":"292","author":"Al-Janabi","year":"2022","journal-title":"Soc Sci Med"},{"issue":"11","key":"10.1016\/j.jval.2022.02.008_bib59","doi-asserted-by":"crossref","first-page":"2847","DOI":"10.1002\/hec.4411","article-title":"Estimating an exchange-rate between care-related and health-related quality of life outcomes for economic evaluation: an application of the wellbeing valuation method","volume":"30","author":"Dhanji","year":"2021","journal-title":"Health Econ"},{"issue":"2","key":"10.1016\/j.jval.2022.02.008_bib60","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1177\/0272989X15605094","article-title":"A\u00a0framework for including Family Health spillovers in economic evaluation","volume":"36","author":"Al-Janabi","year":"2016","journal-title":"Med Decis Making"},{"issue":"4","key":"10.1016\/j.jval.2022.02.008_bib61","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1007\/s40273-019-00786-5","article-title":"Close-person spill-overs in end-of-life care: using hierarchical mapping to identify whose outcomes to include in economic evaluations","volume":"37","author":"Canaway","year":"2019","journal-title":"Pharmacoeconomics"}],"container-title":["Value in Health"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1098301522001103?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1098301522001103?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,22]],"date-time":"2025-10-22T01:27:22Z","timestamp":1761096442000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1098301522001103"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,9]]},"references-count":57,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2022,9]]}},"alternative-id":["S1098301522001103"],"URL":"https:\/\/doi.org\/10.1016\/j.jval.2022.02.008","relation":{},"ISSN":["1098-3015"],"issn-type":[{"value":"1098-3015","type":"print"}],"subject":[],"published":{"date-parts":[[2022,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Systematic Review of Cost-Utility Analyses That Have Included Carer and Family Member Health-Related Quality of Life","name":"articletitle","label":"Article Title"},{"value":"Value in Health","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jval.2022.02.008","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 International Society for Pharmacoeconomics and Outcomes Research, Inc. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}